Obese Teens Taking Popular Weight Loss Medications Are Less Likely to Consider Suicide

JERUSALEM, Israel — Medications like Ozempic and Wegovy can provide a surprising, life-saving benefit to younger patients taking these medications for diabetes and weight loss. Researchers in Israel found that teenagers who use glucagon-like peptide-1 (GLP-1) receptor agonists may have fewer suicidal thoughts and are less likely to attempt self-harm.

This discovery comes at a time when concerns about adolescent mental health are on the rise and the use of weight-loss medications is becoming increasingly common among patients of all ages. The study, published in JAMA Pediatricsspecifically looked at this class of medications, which includes brands such as Ozempic, Wegovy and Mounjaro. Originally created as an effective treatment for diabetes, these medications have gained popularity for their additional ability to help people lose weight by reducing appetite and slowing digestion.

The researchers analyzed the medical records of almost 7,000 teenagers between the ages of 12 and 18 who were diagnosed with obesity. They compared two groups: those who received GLP1R medications and those who received lifestyle interventions, such as diet and exercise advice, without medication.

The surprising results revealed that teens who took GLP1R medications had a 33% lower risk of having suicidal thoughts or attempts over the course of a year, compared to those who did not take the medication. This difference persisted even when researchers analyzed data for up to three years.

The study’s findings are particularly relevant given rising rates of obesity among young people. According to recent data, more than 124 million children and adolescents worldwide are affected by obesity, a number that has increased dramatically in recent decades.

Although the exact reasons for the reduced suicide risk are unclear, researchers have several theories. One possibility is that successful weight loss alone leads to improved mental health and self-esteem. Another theory is that medications may have direct effects on the brain, potentially influencing mood and behavior.

It’s important to note that the study found some expected side effects of the medications. Teens taking GLP1R medications are more likely to experience gastrointestinal symptoms such as nausea and vomiting. However, they had a lower risk of acute pancreatitis, a potentially serious condition that has been linked to these medications in some cases.

The researchers warn that although these results are promising, more studies are needed to confirm the results and understand the long-term effects of these medications on adolescent mental health. They also emphasize that medication should be part of a comprehensive approach to treating obesity, which includes diet, exercise and behavioral support.

As the debate continues over the use of weight loss medications in young people, this study adds an important piece to the puzzle. This suggests that for some teens struggling with obesity, these medications may offer benefits that go beyond simple weight loss.